Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Laura Sargentini-Maier

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|May 8, 2013
Brivaracetam disposition in mild to severe hepatic impairmentArmel Stockis, Maria Laura Sargentini-Maier, Yves Horsmans
Epilepsy Research|September 14, 2007
Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rulesEric Snoeck, Philippe Jacqmin, Maria Laura Sargentini-Maier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2007
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjectsMaria Laura Sargentini-Maier, Pascal Espié, Alain Coquette, et al.
Clinical Pharmacokinetics|May 24, 2007
Population pharmacokinetics of levetiracetam in Japanese and Western adultsEtienne Pigeolet, Philippe Jacqmin, Maria-Laura Sargentini-Maier, et al.
British Journal of Clinical Pharmacology|March 18, 2008
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menPaul Rolan, Maria Laura Sargentini-Maier, Etienne Pigeolet, et al.
Drug Metabolism Reviews|July 16, 2009
Population pharmacokinetic and pharmacodynamic analysis in allergic diseasesMark Lovern, Maria-Laura Sargentini-Maier, Christian Otoul, et al.
Clinical Pharmacology in Drug Development|May 22, 2023
Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly ParticipantsArmel Stockis, Jean-Marie Nicolas, Maria Laura Sargentini-Maier, et al.
Clinical Pharmacokinetics|April 11, 2008
Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendationsNathalie Toublanc, Maria Laura Sargentini-Maier, Brigitte Lacroix, et al.
Journal of Clinical Pharmacology|January 12, 2012
Brivaracetam disposition in renal impairmentMaria Laura Sargentini-Maier, Antoni Sokalski, Pierre Boulanger, et al.
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|May 8, 2013
Brivaracetam disposition in mild to severe hepatic impairmentArmel Stockis, Maria Laura Sargentini-Maier, Yves Horsmans
Epilepsy Research|September 14, 2007
Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rulesEric Snoeck, Philippe Jacqmin, Maria Laura Sargentini-Maier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2007
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjectsMaria Laura Sargentini-Maier, Pascal Espié, Alain Coquette, et al.
Clinical Pharmacokinetics|May 24, 2007
Population pharmacokinetics of levetiracetam in Japanese and Western adultsEtienne Pigeolet, Philippe Jacqmin, Maria-Laura Sargentini-Maier, et al.
British Journal of Clinical Pharmacology|March 18, 2008
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menPaul Rolan, Maria Laura Sargentini-Maier, Etienne Pigeolet, et al.
Drug Metabolism Reviews|July 16, 2009
Population pharmacokinetic and pharmacodynamic analysis in allergic diseasesMark Lovern, Maria-Laura Sargentini-Maier, Christian Otoul, et al.
Clinical Pharmacology in Drug Development|May 22, 2023
Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly ParticipantsArmel Stockis, Jean-Marie Nicolas, Maria Laura Sargentini-Maier, et al.
Clinical Pharmacokinetics|April 11, 2008
Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendationsNathalie Toublanc, Maria Laura Sargentini-Maier, Brigitte Lacroix, et al.
Journal of Clinical Pharmacology|January 12, 2012
Brivaracetam disposition in renal impairmentMaria Laura Sargentini-Maier, Antoni Sokalski, Pierre Boulanger, et al.
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
Pageof 2